Peptide YY (Human, 3-36)

<strong>Peptide YY (Human, 3-36)</strong> <strong>Catalog number:</strong> MDP0766 <strong>CAS Number: </strong>154947-66-7 <strong>Sequence: </strong>Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH2 <strong>Amount:</strong> 500 ug <strong>Molecular Weight:</strong> 4049.2 g/mol <strong>Supplied as:</strong> Powder <strong>Applications:</strong> molecular tool for various biochemical applications <strong>Storage:</strong> -20 °C <strong>WARNING:</strong> For in vitro Research Use Only. NOT for use on humans or animals. <strong>Grade:</strong> Biotechnology grade. All products are highly pure. <strong>References:</strong> 1: Camilleri M, Acosta A. Combination Therapies for Obesity Metab Syndr Relat Disord. 2018 Oct;16(8):390-394. 2: Lustig RH, Collier D, Kassotis C, Roepke TA, Kim MJ, Blanc E, Barouki R, Bansal A, Cave MC, Chatterjee S, Choudhury M, Gilbertson M, Lagadic-Gossmann D, Howard S, Lind L, Tomlinson CR, Vondracek J, Heindel JJ. Obesity I: Overview and molecular and biochemical mechanisms Biochem Pharmacol. 2022 May;199:115012. 3: Tam FI, Seidel M, Boehm I, Ritschel F, Bahnsen K, Biemann R, Weidner K, Roessner V, Ehrlich S. Peptide YY(3-36) concentration in acute- and long-term recovered anorexia nervosa Eur J Nutr. 2020 Dec;59(8):3791-3799. 4: Steinert RE, Feinle-Bisset C, Asarian L, Horowitz M, Beglinger C, Geary N. Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB Physiol Rev. 2017 Jan;97(1):411-463. 5: Bech EM, Kaiser A, Bellmann-Sickert K, Nielsen SS, Sørensen KK, Elster L, Hatzakis N, Pedersen SL, Beck-Sickinger AG, Jensen KJ. Half-Life Extending Modifications of Peptide YY(3-36) Direct Receptor-Mediated Internalization Mol Pharm. 2019 Aug 5;16(8):3665-3677. 6: Shao J, Chen MJ, Kuehl PJ, Hochhaus G. Pharmacokinetic and pharmacodynamic modeling of gut hormone peptide YY((3-36)) after pulmonary delivery Drug Dev Ind Pharm. 2019 Jul;45(7):1101-1110. 7: Ballantyne GH. Peptide YY(1-36) and peptide YY(3-36): Part I. Distribution, release and actions Obes Surg. 2006 May;16(5):651-8. 8: Papadimitriou MA, Krzemien AA, Hahn PM, Van Vugt DA. Peptide YY(3-36)-induced inhibition of food intake in female monkeys Brain Res. 2007 Oct 17;1175:60-5. 9: Ballantyne GH. Peptide YY(1-36) and peptide YY(3-36): Part II. Changes after gastrointestinal surgery and bariatric surgery Obes Surg. 2006 Jun;16(6):795-803. <a href="https://pubmed.ncbi.nlm.nih.gov/21251093">10: Hankir MK, Parkinson JR, Minnion JS, Addison ML, Bloom SR, Bell JD. Peptide YY 3-36 and pancreatic polypeptide differentially regulate hypothalamic neuronal activity in mice in vivo as measured by manganese-enhanced magnetic resonance imaging J Neuroendocrinol. 2011 Apr;23(4):371-80. </a> <br><strong>Products Related to Peptide YY (Human, 3-36) can be found at</strong> <a href="https://moleculardepot.com/product-category/Peptides/"> Peptides</a>